Evidence map›Paper›PMID 26152360›Full record

ArticleNeoplasia (New York, N.Y.)2015

Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.

Min Woo Seong, Seung Hyeun Ka, Ji Ho Park, Jong Ho Park, Hee Min Yoo, Seung Wook Yang, Jung Mi Park, Dongeun Park, Soon Tae Lee, Jae Hong Seol and 1 more

Open access · goldAbstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Min Woo SeongSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Seung Hyeun KaSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Ji Ho ParkSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Jong Ho ParkSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Hee Min YooSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Seung Wook YangSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Jung Mi ParkSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Dongeun ParkSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea.
Soon Tae LeeDepartment of Neurology, Seoul National University Hospital, Seoul, Korea.
Jae Hong SeolSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea. Electronic address: jhseol@snu.ac.kr.
Chin Ha ChungSchool of Biological Sciences and Institute for Protein Metabolism and Diseases, College of Natural Sciences, Seoul National University, Seoul, Korea. Electronic address: chchung@snu.ac.kr.
Seoul National University · KRSeoul National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

c-Cbl, a RING-type ubiquitin E3 ligase, downregulates various receptor tyrosine kinases (e.g., epidermal growth factor receptor (EGFR)), leading to inhibition of cell proliferation. Moreover, patients with myeloid neoplasm frequently harbor c-Cbl mutations, implicating the role of c-Cbl as a tumor suppressor. Recently, we have shown that c-Cbl downregulates αPix-mediated cell migration and invasion, and the lack of c-Cbl in the rat C6 and human A172 glioma cells is responsible for their malignant behavior. Here, we showed that c-Cbl exon skipping occurs in the glioma cells and the brain tissues from glioblastoma patients lacking c-Cbl. This exon skipping resulted in generation of two types of c-Cbl isoforms: type I lacking exon-9 and type II lacking exon-9 and exon-10. However, the c-Cbl isoforms in the cells and tissues could not be detected as they were rapidly degraded by proteasome. Consequently, C6 and A172 cells showed sustained EGFR activation. However, no splice site mutation was found in the region from exon-7 to exon-11 of the c-Cbl gene in C6 cells and a glioblastoma tissue lacking c-Cbl. In addition, c-Cbl exon skipping could be induced when cells transfected with a c-Cbl mini-gene were grown to high density or under hypoxic stress. These results suggest that unknown alternations (e.g., mutation) of splicing machinery in C6 and A172 cells and the glioblastoma brain tissues are responsible for the deleterious exon skipping. Collectively, these findings indicate that the c-Cbl exon skipping contributes to human glioma and its malignant behavior.

Indexed as

ExonsGene Expression Regulation, NeoplasticAnimalsBlotting, WesternErbB ReceptorsGliomaHumansHypoxiaImmunoprecipitationMutationProto-Oncogene Proteins c-cblRatsReal-Time Polymerase Chain ReactionRegulatory Elements, TranscriptionalReverse Transcriptase Polymerase Chain ReactionRNA, MessengerCBL protein, humanEGFR protein, humanErbB ReceptorsProto-Oncogene Proteins c-cblRNA, Messenger

Identifiers

PMID26152360
PMCPMC4719003
OpenAlexW1917602659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.